Key result
Treatment with ACEIs and ARBs appears promising for preventing atrial fibrillation in essential hypertension, particularly in patients with structural heart disease or left ventricular dysfunction.
Why the study?
Do ACEIs and ARBs prevent the onset and recurrence of atrial fibrillation in patients with essential hypertension?
Do ACEIs and ARBs prevent the onset and recurrence of atrial fibrillation in patients with essential hypertension?
ACEIs and ARBs may help prevent atrial fibrillation in hypertensive patients, particularly those with concurrent structural heart disease or left ventricular dysfunction.
No takes yet. Share an insight, caveat, or question.
Does not support routine AF prevention use in hypertension; leaves open need for RCTs in structural heart disease.
Zhao et al. (2014) conducted a review in Atrial fibrillation in essential hypertension. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) was evaluated. Treatment with ACEIs and ARBs appears promising for preventing atrial fibrillation in essential hypertension, particularly in patients with structural heart disease or left ventricular dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: